Oxyfer 750 mg Injection should be administered intravenously by slow infusion or slow injection by a healthcare professional. It should be diluted in 0.9% sodium chloride solution prior to infusion. Never administer as a rapid IV bolus due to the risk of hypotensive reactions. Observe patients for signs of hypersensitivity during and after administration.

Iron sucrose dissociates into iron and sucrose. The iron component is then transported to the body's iron stores (e.g., bone marrow, liver, spleen) where it is incorporated into hemoglobin, myoglobin, and iron-containing enzymes. Sucrose is metabolized.

• •Known hypersensitivity to iron sucrose or any of its components.
• •Anemias not caused by iron deficiency (e.g., hemolytic anemia, vitamin B12 deficiency).
• •Iron overload (e.g., hemochromatosis, hemosiderosis) or disturbances in iron utilization.
• •First trimester of pregnancy (due to potential risks of anaphylaxis).

Store at room temperature (20-25°C). Do not freeze. Protect from light. Do not mix with other medications or use if particulate matter is present.

Overdose of iron sucrose can lead to iron overload (hemochromatosis), which can be severe and life-threatening. Symptoms may include hypotension, collapse, nausea, vomiting, and abdominal pain. Management involves discontinuing the drug, supportive care, and, if severe, iron chelation therapy (e.g., deferoxamine).

Pregnancy Category B. Studies in pregnant animals have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use with caution during the second and third trimesters if clearly needed. Avoid during the first trimester. Use with caution in breastfeeding mothers; benefits should outweigh potential risks.